University of Florida
The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.
Inclusion Criteria: * Patients with high bleeding risk (defined according to the ARC-HBR criteria) who have undergone PCI and are on maintenance treatment with DAPT, consisting of low-dose aspirin (81mg qd) with clopidogrel (75 mg qd) as part of standard of care for at least 30 days. * Age ≥18 years. * Provide written informed consent. Exclusion Criteria: * Prior cerebrovascular event. * PCI within 30 days. * Hemodynamic instability. * On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at ven…
Prasugrel 5 mg od for 30 ± 5 days
Clopidogrel 75 mg od for 30 ± 5 days
Arctuva estimate
Verify or correct the compensation shown for this listing.